

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/061111 A1

(51) International Patent Classification⁷: C12N 15/64,
C12Q 1/68

(21) International Application Number:
PCT/US2003/039584

(22) International Filing Date:
11 December 2003 (11.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/324,780 19 December 2002 (19.12.2002) US

(71) Applicant (for all designated States except US): **THE
SCRIPPS RESEARCH INSTITUTE** [US/US]; 10550
North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GHADIRI, Reza,
M.** [US/US]; 5133 Seagrove Court, San Diego, CA 92130
(US). **MIYAKE, Masato** [JP/JP]; 3-15-1-106 Nakoji, Am-
agasaki, Hyogo 661-0974 (JP).

(74) Agents: **FITTING, Thomas et al.**; The Scripps Research
Institute, 10550 North Torrey Pines Road, TPC-8, La Jolla,
CA 92037 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 2004/061111 A1

(54) Title: DNA ARRAY FOR HIGH THROUGHPUT SOLID-PHASE TRANSFECTION AND METHOD FOR PRODUCING
THE SAME

(57) Abstract: The present invention relates to a DNA array for high throughput and highly efficient solid-based transfection which
comprises a plurality of dried spots on a solid support, said dried spot comprises (1) a plasmid DNA to be introduced into cells, (2)
a transfection reagent and (3) a cell-adhesion protein and to a high throughput and highly efficient solid-based transfection method
to introduce plasmid DNA into cells, using the same.

DNA ARRAY FOR HIGH THROUGHPUT SOLID-PHASE TRANSFECTION AND
METHOD FOR PRODUCING THE SAME

Technical field

5 This invention relates to a DNA array for high
throughput solid-phase transfection system, a method for
producing the DNA array, reagents to be used for producing the
DNA array, and a method for carrying out solid-phase high
throughput transfection using the DNA array.

10

Background art

Hitherto, liquid-phase based transfection system has
been used for introduction of DNA into mammalian cells. The
following methods have been used for transfection of mammalian
15 cells so far.

- (1) Calcium phosphate coprecipitation method (Chen, C. and
Okayama, H.: Biotech., 6, 632-638, 1988),
- (2) Lipofection-mediated transfer method (Rabindran S.K. et.
al. : Science 259, 230-234, 1993),
- 20 (3) DEAE dextran-mediated transfer method (Sussman, D.J. and
Milman, G.: Mol. Cell. Biol., 4, 1641-1643, 1984),
- (4) Electroporation method (Chu, G. et. al.: Nuc. Acid. Res.,
15, 1311-1326, 1987), and
- (5) Microinjection method (Graessmann, M. and Graessmann A.:
25 Proc. Natl. Acad. Sci. USA, 73, 366-370, 1976).

The above mentioned methods (1) to (4) need 10^4 to 10^6
cells as well as 0.1 to 10 μ g DNA, in which the transfection
efficiency is the maximal level of about 20%, although it is
difficult to maintain the maximal transfection efficiency
30 under various conditions. Especially, transfection
efficiencies are variable depending on cell types and these
transfection procedures are complicated and time-consuming.
Under these circumstances, it is almost impossible to
establish a high throughput transfection method by
35 miniaturization and automation of the above mentioned

transfection systems (1) to (4). In the meanwhile, the above mentioned method (5) requires much lesser amount of cells and DNA for transfection than the above mentioned methods (1) to (4), however, the procedure requires a high level of skill and a long-term experience since microinjection of DNA into cells is directly carried out under an observation with a microscope. Therefore, a liquid-phase transfection system is not suitable for high throughput transfection.

At present, a high throughput transfection system is highly required as shown in the following example: When cell proliferation is initiated by addition of various stimulations, the successive signal transductions are controlled by networks of interacting proteins.

Signal transduction and processing generally take place through specific protein-protein interactions mediated by protein structural transition and/or chemical transformations. Because of the complexity and our present incomplete understanding of protein circuitry and network dynamics and function, correlating a particular phenotype to a set of protein-protein interactions is not only a major undertaking but often requires methods that are amenable to genome-wide or targeted network analysis. The technology is highly required to analyze networks of interacting proteins encoded by the entire human genome. If high throughput transfection and monitoring systems are established, it is possible to express a target gene, to monitor the level of a gene product and to analyze the effect of the gene expression on cellular function in intact cells in real time.

The solid phase transfection technology is preferable to this purpose. In fact, J. Ziauddin and D. M. Sabatini have reported the solid phase-transfection method (Junaid Ziauddin & David M. Sabatini: Microarrays of cells expressing defined cDNAs, Nature 411, 107-110, 2001). In this paper, geratin is used to transfect DNA into cells by forming DNA-geratin complex to fuse with cell membrane. However, the method

covers only a few cell lines, and has a problem for reproducibility and transfection efficiency.

Therefore, an object of the present invention is to provide a DNA array for high throughput solid-phase
5 transfection, and a method for carrying out high throughput solid-phase transfection using the DNA array, which solve the above-mentioned problems.

Disclosure of the invention

10 The present invention is based on the finding that transfection efficiency is remarkably improved and cross-contamination is highly reduced in the presence of a cell-adhesion protein in dried spots printed on a surface of a solid support, which contain plasmid DNAs.

15 Accordingly, a solid-phase transfection method of the present invention can be carried out by the following procedures:

- 20 (a) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells, a transfection reagent, and a cell-adhesion protein,
- (b) spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations,
- 25 (c) allowing the DNA-containing mixture to dry on the surface of the solid support,
- (d) plating cells onto the surface of the solid support, and
- (e) maintaining the solid support and the cells under
30 appropriate conditions for transfection to proceed efficiently.

or

- 35 (a) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells, and a cell-adhesion protein,

- (b) spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations,
- (c) allowing the DNA-containing mixture to dry on the surface of the solid support,
- 5 (d) exposing the printed solid support to the diluted transfection reagent,
- (e) plating cells onto the surface of the solid support, and
- 10 (f) maintaining the solid support and the cells under appropriate conditions for transfection to proceed efficiently.

Further, the present invention relates to a DNA array for transfection which comprises a plurality of dried spots on a solid support, said dried spot comprises (1) a plasmid DNA to be introduced into cells, (2) a transfection reagent and (3) a cell-adhesion protein.

Still further, the present invention relates to a method for producing a DNA array, comprising:

- 20 (a) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells, a transfection reagent, and a cell-adhesion protein,
- (b) spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations,
- 25 (c) allowing the DNA-containing mixture to dry on the surface of the solid support.

In addition, the present invention relates to a reagent kit for manufacturing the above mentioned DNA array, which comprises (1) a plasmid DNA to be introduced into cells, (2) a transfection reagent, and (3) a cell-adhesion protein.

Finally, the present invention relates to a method for gene profiling in cells, comprising:

- 35 (a) plating cells onto the surface of the above mentioned DNA array,

- (b) maintaining the adhered cells on plasmid under conditions appropriate for cell proliferation,
- (c) expressing transfected genes in cells, and
- (d) monitoring an exogenously produced protein and
5 detecting changes of cellular phenotypes due to the expression of the protein.

According to the present invention, introduction of DNA into cells become highly efficient, cross-contamination detected as a signal from the neighboring places become
10 negligible, and the solid-phase transfection system using DNA array provides high throughput transfection system. Based on the above mentioned findings, profiling a gene product expressed in cells, monitoring a change of cell phenotype, and analyzing a network of protein-protein interaction in
15 mammalian cells become possible for the first time.

In fact, by a high throughput transfection of peptide-expression library in cells using the present invention, the present inventors have successfully identified a peptide that inhibits specific protein-protein interaction,
20 and analysis of the network pathway using the peptide became possible.

Brief description of the drawings

Figure 1 shows the results of solid-phase transfection efficiency under different plasmid DNA (pEGFP-N1)/cationic lipid (Tfx-20) ratios. The horizontal axis shows a ratio
25 ($\mu\text{g}/\text{nmol}$) of plasmid DNA to cationic lipid and the vertical axis shows a transfection efficiency (%), which is detected as fluorescence of Green Fluorescent Protein (GFP) and
30 calculated by the following equation:

counts of transfected cells/counts of whole cells in a defined location $\times 100$.

Figure 2 shows the results of transfection efficiency at different concentrations and ratios of plasmid DNA and
35 dendrimer.

Figure 3 shows the results for the effect of fibronectin on the transfection efficiency of dendrimer-mediated solid-phase transfection.

Figure 4 shows the results of dendrimer-mediated solid-phase transfection on a compact array.
Figure 4 (a) is a scheme of the array pattern. The square of 1.3 mm x 1.3 mm is demarked by 0.4 mm line of hydrophobic ink. Figure 4 (b) shows HeLa cells adhered on the square. Figure 4 (c) shows Enhanced Green Fluorescent Protein (EGFP) fluorescence image of the HeLa cells of Figure 4(b).

Figure 5 shows the results of the genetic selection of Red Fluorescent Protein (RFP) expression vector on a compact transfection array system based on the dendrimer-mediated solid-phase transfection.

Figure 5 (a) is the scheme of the array pattern: Green, pEGFP was printed; red, pDsRed1 was printed. Figure 5 (b) shows HeLa cells adhered on the array. Figure 5 (c) shows EGFP/RFP image. Figure 5 (d) shows RFP image of the HeLa cells of Figure 5(b).

Figure 6 shows the results of genetic selection of proliferative inhibitor peptides by using the dendrimer-mediated solid-phase transfection system. Figure 6 (a) shows the results of micro-colony counts (slashed bar) and single cell counts (closed bar) on the pEGFP-pep library array. Figure 6 (b) shows the results of frequency of micro-colony in each sample. pEGFP-pep and pEGFP-p21 pep were the negative and the positive controls, respectively.

Best mode for carrying out the invention

The invention is explained in detail hereafter.

The present invention relates to the DNA array occupied by plural dried spots on a solid support, which are consisted of (1) a plasmid DNA to be introduced into cells, (2) a transfection reagent, and (3) a cell-adhesion protein.

As the solid support, there are mentioned a glass plate,

a plastic plate and silicon plate etc., among which a glass plate is preferred. A glass plate may be treated by a poly L-lysine solution.

As the cell adhesion protein (3), fibronectin, pronectin, vitronectin, laminin and collagen etc. are mentioned, in which fibronectin and pronectin are preferred.

As the transfection reagents (2), a cationic lipid, a dendrimer and calcium phosphate etc. are mentioned, in which the cationic lipid and the dendrimer are preferred. The examples of cationic lipids include a polyamine based polymer such as LipofectamineTM (Invitrogen Co., Carlsbad, CA, USA), TransfectamTM (Promega Co., Madison, WI, USA), TfxTM-20 (Promega Co., Madison, WI, USA) and EffecteneTM (QIAGEN Co., Valencia, CA, USA), and a polyimine-based polymer such as Jet PEITM (PolyPlus-transfection, Cedex, France) and ExGenTM 500 (FERMENTAS Inc., Hanover, MD, USA). They are commercially available.

The dendrimer to be used in the present invention is polyamidoamine which has dendrically ramified from the center of a molecule and has positively charged amino group at the ends to interact with negatively charged phosphate group of DNA. As the results, DNA is condensed compactly and the complex is incorporated into cells through endocytosis. Examples of a commercially available dendrimer include PolyFectTM reagent (QIAGEN) and SuperFectTM reagent (QIAGEN).

The plasmid DNA (1) to be introduced into cells comprises randomly selected cDNA and a genomic DNA harboring a coding region in an expression vector. Preferred examples include a plasmid to overexpress a gene and a plasmid to knockout a gene. In addition, the plasmid DNA (1) may include a reporter gene encoding a marker protein. Examples of the marker proteins are Enhanced Green Fluorescent Protein (EGFP), Red Fluorescent Protein (RFP), Luciferase, Secreted alkaline phosphatase (SEAP) and β -galactosidase, in which EGFP and RFP are desirable. Commercially available plasmid-based vectors,

such as pEGFP (Clontech), pDsRed2 (Clontech), pTimer (Clontech) etc. can be used.

Dried spots on the solid support can be obtained by spotting the mixture of (1) a plasmid DNA to be introduced into
5 cells, (2) a transfection reagent and (3) a cell-adhesion protein onto a solid support and by allowing the spotted mixture to dry in air or in vacuo on the surface of the solid support.

Size and shape of the spots are not specifically limited.
10 For example, a diameter of the spots may be from about 0.01 to about 5 mm and a shape of the spot viewed from the above is possibly a circle. Thickness of the dried spots is not specifically limited, and a range of the thickness may be from about 1 to about 100 μm .

15 Number of the spots is not specifically limited, and it may be from about 1 to about 10,000 pieces. It is preferable that each spot contains a different kind of genes in an expression vectors. Each spot is preferably isolated from neighbored spots, for example, by dividing each spot by
20 hydrophobic lines such as Teflon. Each dried spot preferably contains (1) a plasmid DNA to be introduced into cells from about 100 pg/mm^2 to about 1 $\mu\text{g}/\text{mm}^2$, preferably from about 2 to about 200 ng/mm^2 , (2) a transfection reagent from about 0.01 to about 10 $\mu\text{g}/\text{mm}^2$, preferably from 0.1 to 1 $\mu\text{g}/\text{mm}^2$, (3) a
25 cell-adhesion protein from about 0.01 to about 10 $\mu\text{g}/\text{mm}^2$, preferably from 0.1 to about 1 $\mu\text{g}/\text{mm}^2$.

The DNA array of the present invention is obtained by preparing a DNA-containing mixture comprising plasmid DNA to be introduced into cells, a transfection reagent, and a
30 cell-adhesion protein, spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations, allowing the DNA-containing mixture to dry on the surface of the solid support, whereby the plasmid DNA containing mixture affixed to the surface in plural defined
35 discrete locations.

The plasmid DNA to be introduced into cells is prepared, for example, from recombinant Escherichia coli cells. The cell-adhesion protein is, for example, prepared by extraction and purification of recombinant E. coli cells or human/porcine tissues. As the transfection reagent, the above mentioned
5 commercially available products can be used.

A concentration of the plasmid DNA in the DNA-containing mixture is from about 0.01 to about 5 $\mu\text{g}/\mu\text{l}$, preferably from about 0.05 to about 0.5 $\mu\text{g}/\mu\text{l}$. A concentration of the
10 transfection reagent in the DNA-containing mixture is from about 0.01 to about 20 $\mu\text{g}/\mu\text{l}$ preferably from 0.1 to 1 $\mu\text{g}/\mu\text{l}$. Further, a concentration of the cell-adhesion protein in the DNA-containing mixture is from about 0.01 to about 5 $\mu\text{g}/\mu\text{l}$, preferably from 0.1 to 1 $\mu\text{g}/\mu\text{l}$.

15 The preparation of dried spots from the above mentioned DNA-mixture is carried out by spotting on the surface of a solid support using ink-jet type spotter or pin-array type spotter followed by drying in air or in vacuo.

In the solid-phase transfection method of the present
20 invention, after preparing the DNA array as in the above, supply of cells on the surface of the DNA array is carried out by plating cells thereon. The number of cells supplied onto one dried spot is dependent on cell type, preferably about 1 to 10,000, more preferably about 50 to 1,000.

25 Cells supplied onto the dried spots of the DNA array are adhered on the surface of each spot with the aid of adhesion protein, and then, plasmid DNAs affixed to the surface of the solid support enter cells under the conditions appropriate for transfection to occur.

30 The solid-phase transfection method of the present invention is characterized in that it can minimize cross-contamination among the spots, because the cell-adhesion proteins in the spots help cells to be anchored onto the spot.

35 Furthermore, the present invention relates to the

method for gene profiling, which comprises plating cells on the surface of the printed solid support, introducing plasmid DNA into cells maintaining the solid support in the appropriate conditions for transfection to occur, expressing
5 the gene inserted to the expression vector in cells, and detecting the protein in transfected cells, or monitoring a cell phenotype derived from transfected cells.

In the gene profiling of the present invention, the level of proteins expressed in cells are monitored by a desired
10 wavelength using fluorescent microscope. For example, enhanced green fluorescent protein and red fluorescence protein are maximally excited at 488 and 558nm followed by detecting at 509 and 583 nm of maximal fluorescent wavelength, respectively. In the meanwhile, to monitor the cell phenotype
15 derived from transfected cells, for example, cell death is detected under the observation using phase contrast microscope and nuclear staining with propidium iodide.

In the gene profiling of the present invention, for example, screening of peptide is carried out by monitoring
20 cell death during expression of a gene to suppress the gene products essential for cell proliferation. For example, expression of a peptide library encoding a part of the target gene is applicable for suppressing a specific function of a gene product.

25

Examples

In the following, the present invention is explained in more detail by referring to Examples, but the scope of the present invention is not limited to them.

30 Example 1

The representative example of the transfection reagent is cationic lipids, which include TfxTM-20 (Promega, Madison, WI, USA), and EffecteneTM (QIAGEN, Valencia, CA, USA). Both transfection reagents condense and wrap plasmid DNAs in
35 cationic lipids. The complex of plasmid DNA and transfection

reagent is fused with cell membrane and then plasmid DNA is entered inside cells.

The glass plate was prepared as follows: The glass slides (7 cm x 2.5 cm) were marked with 80 squares (2 mm x 2 mm) distinguished by 1-mm Teflon line. The glass slides were treated by incubation for 1 hr in ammonium hydroxide solution (Aldrich, Milwaukee, WI, USA) and washed with distilled water. Then, the glass plates were incubated in poly-L-Lysine solution (10% (v/v) poly-L-lysine solution (Sigma, St. Louis, MO, USA) and 10% (v/v) phosphate buffered saline buffer) for 1 hr and washed with distilled water. The glass plates were air dried and stored in a desiccator until use.

Plasmid samples (pEGFP-N1; Clontech, U.S. Palo Alto, CA) of 1 μ l (0.5 μ g/ μ l in distilled water) were spotted on the glass plates. Plasmids were printed by drying at room temperature. For DNA/cationic lipid complex formation, the printed DNA samples were exposed to the diluted solution of TfxTM-20 transfection reagent for 5 min at room temperature just before transfection. The diluted solution of TfxTM-20 transfection reagent contained 100 μ M of N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3-di(oleoxyloxy)-1,4-butanediammonium iodide.

Cells of 7×10^5 were suspended into 25 ml DMEM preheated at 37°C. The cell suspension was poured into each 100-mm tissue culture dish in which the DNA-printed glass plate was placed. The cells were incubated for 72 hr at 37°C in humidified 5% CO₂ atmosphere. Fluorescent microscopic images of EGFP-expressed cells on the glass plates were taken by an optical camera system (Zeiss). Transfection efficiency was calculated by the equation: transfection efficiency = counts of transfected cells / counts of whole cells x 100 (%). Transfected and whole cells in the photographic images were counted manually and used in the calculation. Cross-contamination frequency on each glass plate was calculated according to the equation: Cross-contamination

frequency (%)=(Counts of transfected cells on the square without printed DNA/counts of transfected cells on the adjacent square containing printed DNA) x 100 (%). The frequency was evaluated by using average value in 8

5 measurements.

The solid-phase transfection efficiency was found to be sensitive to DNA/cationic lipid ratio (Fig. 1). The transfection efficiency was improved by increasing the DNA to cationic lipid ratio up to 5 μg DNA/nmol cationic lipid.

10 Addition of excess amounts of cationic lipid inhibited adherence and growth of HeLa cells, resulting in a decreased level of transfection efficiency. Absolute concentration of DNA/cationic lipid per given surface area also affected the transfection efficiency of HeLa cells. The maximal

15 transfection efficiency was obtained at DNA concentration of 0.13 $\mu\text{g}/\text{mm}^2$. The lower concentration of DNA reduced the transfection efficiency. DNA concentrations of more than 0.13 $\mu\text{g}/\text{mm}^2$ inhibited cell adherence and growth due to the presence of excess amount of cationic lipid on the grid. The

20 highest transfection efficiency by using the optimized protocol described above was 5% (Table 1). However, the average cross-contamination frequency was 44% (Table 1).

Table 1

25

Mediators	Maximal efficiency (%)	Average cross-contamination (%)
Tfx-20 (liposome)	5	44
Effectene (liposome)	2	33
Effectene+Fibronectin	32	5
PolyFect (dendrimer)	3	28
PolyFect+Fibronectin	36	1

Next, pEGFP-N1 (60 ng/ μl) was printed on the poly-L-lysine coated glass slide. At the same time, the glass

slide printed with both pEGFP-N1 (60 ng/ μ l) and human fibronectin (0.8 μ g/ μ l, Nakarai, Tokyo, Japan) were prepared for comparison. The printed DNA samples were exposed to the mixture containing 300 μ l of EC buffer, 16 μ l of Enhancer and
5 60 μ l of Effectene transfection reagent (QIAGEN Co). HeLa cell suspension was plated onto the slide glass, and then, the fluorescence of EGFP in transfected cells was monitored after incubation for 72 hr. Although the transfection efficiency is 2% and the cross-contamination was 40% in the spot
10 containing pEGFP-N1 alone, the former increased to 32% and the latter was decreased to 5% in the spot containing both pEGFP-N1 and fibronectin (Table 1 shows the comparison of solid-phase transfection systems using Tfx-20 cationic lipid (liposome), Tfx-20 + Fibronectin, Polyfect (dendrimer), and
15 Polyfect+Fibronectin as mediators.). The addition of fibronectin to the DNA was highly efficient to increase transfection efficiency and to minimize cross-contamination.

Example 2

20 PolyFectTM transfection reagent (QIAGEN Co.) is consisted of an active dendrimer molecules which is diverged from a center of the molecule and have positively charged amino groups at the branched termini to interact with phosphate groups of DNA. PolyFectTM reagent makes DNA to condense in
25 compact form which is easily incorporated into cells by endocytosis.

DNA/PolyFect ratio in the DNA printing mixture (minus fibronectin) was investigated to obtain the highest transfection efficiency (Fig. 2). Inhibition of adherence
30 and growth of HeLa cells was observed at concentrations of PolyFect in excess of 1.0 μ g/mm². At 0.5 μ g/mm² of PolyFect, relatively high transfection efficiency was observed using 0.1 to 0.4 μ g /mm² DNA. Larger or lower concentrations of PolyFect resulted in relatively low transfection efficiency
35 probably due to the presence of excess charge on the surface

and/or the non-optimal particle size of DNA/dendrimer complex for of HeLa cell transfection. The maximal transfection efficiency was 3% in the range of the optimal DNA/PolyFect ratio (Table 1). However, the average cross-contamination
5 frequency was at an unacceptable level of 28% (Table 1).

The efficiency of dendrimer-mediated solid-phase transfection was dramatically increased by the addition of fibronectin (Fig. 3). The addition of fibronectin also virtually eliminated the cross-contamination frequency. The
10 average frequency of cross-contamination at 0.25 $\mu\text{g}/\text{mm}^2$ of fibronectin was 1% (Table 1). The effect of fibronectin on the transfection efficiency and cross-contamination frequency most likely results from acceleration of adherence of HeLa cells, since fibronectin is an epithelial cell
15 attachment factor.

Example 3

The DNA printing and complex formation procedures for cationic lipid and dendrimer-mediated solid-phase
20 transfection systems are different. In the cationic lipid-mediated solid-phase transfection procedure, DNA was printed first, then, the DNA/cationic lipid complex was formed on the solid glass support. The physical process of exposing DNA to cationic lipids most likely increased the chance of
25 cross-contamination of DNA between adjacent grid locations.

On the contrary, in the case of the dendrimer-mediated solid-phase transfection, DNA/dendrimer complex is directly printed on the glass plates. This is a simpler process than the cationic lipid-mediated system and reduced the chance of
30 cross-contamination. In fact, the average frequency of cross-contamination in the dendrimer-mediated system was lower than the cationic lipid-mediated system (Table 1). The results suggest that the dendrimer-mediated system is well-suited for high-throughput transfection system. The
35 use of fibronectin for dendrimer-mediated system allows the

design of a high density DNA array for use in high-throughput solid-phase transfections.

Example 4

5 A compact DNA array was developed based on the dendrimer/fibronectin-mediated solid-phase transfection system (Fig. 4). The density of the pattern allows to print 800 plasmid samples on a slide glass (7 cm x 2.5 cm). It should be noted that two fold higher density will not afford
10 statistically significant number of adhered and/or transformed cells per grid to be useful in genetic selection studies. 0.5 µl of the DNA printing mixture, which contained 40 ng pEGFP-pep (details are described in Example 5), 0.2 µg fibronectin, was spotted in each square. After plating HeLa
15 cells onto the slide glass, 25 µl of gene expression inducer (2mg/ml doxycycline) was added into the cell suspension. The cells adhered on the glass plate very well (Fig. 4. (b)). Transfected cells expressed EGFP were observed in the area that DNA was printed (Fig. 4. (c)). The transfection
20 efficiency was 10.5%.

Cross-contamination of the compact array system was examined by using EGFP expression vector (pEGFP-N1) and a red fluorescent protein (RFP) expression vector (pDsRed1 vector, Clontech, Palo Alto CA) (Fig. 5). The DNA printing mixtures
25 of pEGFP and pDsRed1 optimized for the compact array were spotted as shown in Fig. 5 (a). As shown in Fig. 5 (b), HeLa cells adhered on the glass surface and the hydrophobic lines demarking the grids. EGFP expressed cells were frequently
30 observed in the squares on which the pEGFP was printed (Fig. 5 (c)). RFP expressed cells were observed only in the squares on which the pDsRed1 was printed (Fig. 5. (d)). In the sets of experiment, there were no cross-contamination between EGFP expressed cells and RFP expressed cells. The demonstration
35 indicates that the dendrimer-mediated solid-phase

transfection developed for the compact array system can be applied for accurate genetic selection.

Example 5

5 The pTRE2 vector (Clontech Col.) contains the CMV promoter together with TRE (tetracycline response element) in which the addition of either doxycyclin or tetracycline is required for a gene expression under the control of the CMV promoter. Peptide-EGFP fused protein expression vector,
10 pEGFP-pep was constructed by ligation of the 3.8 kb fragment of pTRE2 digested with XbaI with 0.8 kb fragment encoding EGFP prepared by digestion with XbaI. Plasmids coding randomized peptide EGFP fusion proteins were prepared based on primer extension methods: template DNAs
15 (5'-AAACCGCGGATGTGTAAACGGCGGCAGACCAGCGCTACAGATTTCTACCACTCCARRARRRRDTADTATWTTCTGCGGATCGATAAA-3') were denatured at 94°C for 10min and annealed with primer DNA (5'-TTTATCGATCCGCA-3') in TE buffer at 4°C overnight. Primer extension reaction of the annealed DNA samples was carried out
20 at 37°C for 30 min in the presence of 10 µg/ml DNAs, 100 units/ml Klenow fragment (New England Biolabs, Beverly, MA, USA), 10 mM Tris-HCl (pH 7.5), 5 mM MgCl₂, 7.5 mM dithiothreitol. The reaction products were digested by SacII and ClaI, then purified by QIAquick PCR purification kit (QIAGEN, Valencia,
25 CA, USA). The SacII-ClaI fragments were cloned into the SacII-ClaI site in pEGFP-pep. The plasmids cloned in Escherichia coli XL1-blue were purified by QIAprep kit (QIAGEN, Valencia, CA, USA) and eluted by distilled water from the QIAprep columns. Concentration of each plasmid solution was
30 adjusted to 0.5 µg/µl for cationic lipid-mediated transfection and 0.2 µg/µl for dendrimer-mediated transfection by dilution with distilled water and was used for solid-phase transfection experiments. The biased plasmid library constructed here encodes CDK-cyclin binding peptide
35 derivatives designed from p21waf1/cip1 G1 cell cycle

checkpoint protein (Toyashima, H. and Hunter T.: Cell, 78, 67-74, 1994). The plasmid library was printed on a glass plate (80 squares, 2 mm x 2 mm). Fig. 6 shows the example results of the genetic selection of proliferative inhibitor peptides from 14 plasmids. After the solid-phase transfection as shown in Example 4, the cells were fixed by exposing to paraformadldehyde solution (4% in PBS buffer) for 15 min at room temperature. Then the cells were exposed to 0.5% Triton X-100 for 30 sec and were washed twice with PBS buffer. For image-based selection, the cells were stained with propidium iodide (PI) by exposing to PI solution (20 µg/ml PI, 200 µg ribonuclease A per 1 ml of PBS buffer) for 30 min at room temperature. In the EGFP expressed cells, microcolony, which is defined as duplicating cell (including S, M and G2 phase), and G1 cells were counted manually. The number of transfected cells was variable in each square (Fig. 6a) probably due to small differences in the DNA printing conditions, However, the frequency of micro-colony on the pEGFP-pep printed area was 15% and the frequencies of micro-colony on the areas printed with negative peptide coding vecgtors were within the range of 10-20% (Fig.6b). However, the frequency on the positive peptide-coding vector (#11) was 5% and was similar to the observed 6% frequency of the positive control grid (pEGFP-p21 pep). These examples indicate that the transfected cells on the array changed their phenotypes by the effect of expressed peptides. The above proof of principle study suggests that the transfection array system is a novel and powerful tool for high-throughput genetic selection with mammalian cells.

30 Industrial Applicability

The present invention is applicable for a gene network analysis which is the most important subject in post-genome sequencing period. If the data base of the gene network is constructed once, the value is extremely high based on the application to drug discovery, medicare, diagnostics and food

industry. In addition, the contracted service based on gene network data base is highly possible.

The present invention can be used to identify aptamers or peptides which inhibit protein-protein interaction
5 specifically. They may be possible candidates for medicine, diagnostic reagent or reagent for research tool. Especially, either peptide-mimetics or low molecular weight compounds may be synthesized based on the sequence of the peptide, which will be a candidate for a drug to cure or prevent disease.
10 In addition, the present invention provides a novel tool to find a new target for drug discovery.

Claims

1. A DNA array for transfection which comprises a plurality of dried spots on a solid support, said dried spot comprises
 - 5 (1) a plasmid DNA to be introduced into cells, (2) a transfection reagent and (3) a cell-adhesion protein.
2. The DNA array of claim 1, wherein (3) the cell-adhesion protein is fibronectin.
- 10 3. The DNA array of claim 1, wherein (2) the transfection reagent is selected from the group consisting of a cationic lipid and a dendrimer.
- 15 4 The DNA array of claim 1, wherein (1) the plasmid DNA to be introduced into cells further comprises a reporter gene.
5. A method for producing the DNA array of claim 1 comprising:
 - 20 (d) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells, a transfection reagent, and a cell-adhesion protein,
 - (e) spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations,
 - 25 (f) allowing the DNA-containing mixture to dry on the surface of the solid support.
6. A reagent kit for manufacturing the DNA array of claim 1, which comprises (1) a plasmid DNA to be introduced into cells,
 - 30 (2) a transfection reagent, and (3) a cell-adhesion protein.
7. A solid-phase transfection method comprising:
 - 35 (a) plating cells onto the surface of the DNA array of claim 1, and

- (b) maintaining the DNA array and the cells under appropriate conditions for transfection to proceed efficiently.
- 5 8. A solid-phase transfection method comprising:
- (a) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells, a transfection reagent, and a cell-adhesion protein,
 - 10 (b) spotting the DNA-containing mixture on a surface of a solid support in a plurality of defined locations,
 - (c) allowing the DNA-containing mixture to dry on the surface of the solid support,
 - 15 (d) plating cells onto the surface of the solid support, and
 - (e) maintaining the solid support and the cells under appropriate conditions for transfection to proceed efficiently.
- 20 9. The solid-phase transfection method of claim 8, wherein the cell-adhesion protein is fibronectin.
10. The solid-phase transfection method of claim 9, wherein the transfection reagent is a dendrimer.
- 25 11. A solid-phase transfection method comprising:
- (a) preparing a DNA-containing mixture comprising a plasmid DNA to be introduced into cells and cell-adhesion protein,
 - (b) spotting the DNA-containing mixture on a surface
30 of a solid support in a plurality of defined locations,
 - (c) allowing the DNA-containing mixture to dry on the surface of the solid support,
 - (d) exposing the dried DNA-containing mixture of step
35 (c) to a solution containing a transfection

reagent,

(e) plating cells onto the surface of the solid support,
and

5 (f) maintaining the solid support and the cells under
appropriate conditions for transfection to
proceed efficiently.

12. The solid-phase transfection method of claim 11, wherein
the cell-adhesion protein is fibronectin.

13. The solid-phase transfection method of claim 12, wherein
10 the transfection reagent is a cationic lipid.

14. A method for gene profiling in cells, comprising:

(a) plating cells onto the surface of the DNA array
of claim 1,

15 (b) maintaining the adhered cells on plasmid under
conditions appropriate for cell proliferation,


(c) expressing transfected genes in cells, and

(d) monitoring an exogenously produced protein and
detecting changes of cellular phenotypes due to the
expression of the protein.

20 15. A method of claim 8 to be used for a network analysis,
screening of seed compounds for drug discovery, and discovery
of a novel diagnostic marker.


1/6

Figure 1




SUBSTITUTE SHEET (RULE 26)

FIG. 2



3/6



SUBSTITUTE SHEET (RULE 26)

FIG. 4B




FIG. 4C





FIG. 4A



SUBSTITUTE SHEET (RULE 26)

5/6

FIG. 5B




FIG. 5D



FIG. 5A




FIG. 5C





FIG. 6



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/39584

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/64, C12Q 1/68
US CL : 435/458, 6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/458, 6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BRS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZIAUDDIN, J. et al. Microarrays of cells expressing defined cDNAs. Nature. 03 May 2001, Vol. 411, pages 107-110. See entire document.	1-15

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 March 2004 (04.03.2004)

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230

Date of mailing of the international search report

27 MAY 2004

Authorized officer
James S. Ketter
Telephone No. (703) 308-0196